MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study (Q27852083)

8

0 references

Reinhard Dummer

15

0 references

Paolo Antonio Ascierto

1

object named as

Paolo A Ascierto

0 references

Christian U Blank

7

object named as

Christian U Blank

0 references

author name string

Carola Berking

3

0 references

Sanjiv S Agarwala

4

0 references

Carla Ml van Herpen

5

0 references

Paola Queirolo

6

0 references

J Thaddeus Beck

9

0 references

Annie St-Pierre

10

0 references

Faiz Niazi

11

0 references

Simon Wandel

12

0 references

Malte Peters

13

0 references

Angela Zubel

Lancet Oncology Commission

14

0 references

publication date

March 2013

0 references

published in

0 references

volume

14

0 references

issue

3

0 references

page(s)

249-56

0 references

cites work

Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

NRAS mutation status is an independent prognostic factor in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

The European Academy of Cancer Sciences

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

MEK1 mutations confer resistance to MEK and B-RAF inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Distinct sets of genetic alterations in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Somatic activation of KIT in distinct subtypes of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970024-X

7 January 2021

10.1016/S1470-2045(13)70024-X

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

32851

32851

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference